Champions Oncology Reports Significant Q3 Net Loss, Negative Operating Cash Flow, and Deteriorating Working Capital

summarizeSummary

Champions Oncology reported a net loss for Q3, a decline in quarterly revenue, and a significant year-to-date operating cash burn, leading to negative working capital, despite management's twelve-month liquidity assurance.

check_boxKey Events

• Swing to Net Loss in Q3

  The company reported a net loss of $0.279 million for the three months ended January 31, 2026, a significant decline from a net income of $4.495 million in the same period last year.

• Q3 Revenue Decline

  Oncology revenue for Q3 2026 decreased by 2.8% to $16.559 million, down from $17.039 million in Q3 2025, primarily due to the lack of large data license transactions.

• Significant Operating Cash Burn

  For the nine months ended January 31, 2026, Champions Oncology used $2.474 million in cash from operating activities, a substantial reversal from generating $0.518 million in the prior year period.

• Negative Working Capital

  The company reported a negative working capital of $0.492 million as of January 31, 2026, indicating short-term liquidity challenges, although this is an improvement from a larger deficit in the prior fiscal year.

auto_awesomeAnalysis

Champions Oncology's latest 10-Q reveals a concerning financial performance, marked by a significant swing from profitability to a net loss in Q3 and a substantial cash burn from operations year-to-date. The company reported a net loss of $0.279 million for the quarter, a sharp decline from a $4.495 million net income in the prior year. This was accompanied by a 2.8% decrease in quarterly revenue, primarily due to the absence of large data license transactions. For the nine months ended January 31, 2026, the company used $2.474 million in cash from operations, a stark reversal from generating cash in the prior year, and reported a negative working capital of $0.492 million. While management asserts that current cash and expected cash flows are adequate for at least the next twelve months, these deteriorating financial metrics, especially with the stock trading near its 52-week low, signal increased financial pressure and potential challenges in funding future growth initiatives without external capital.